Escape Phenomenon of the Antihypertensive Therapy Efficacy

The Role of Ambulatory Blood Pressure Characteristics, Features of the Structural and Functional Vascular Wall State, the Presence and Severity of Obstructive Sleep Apnea Syndrome in Predicting the Escape Phenomenon of the Antihypertensive Therapy Efficacy.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05436730

Acronym

ESCAPE

Enrollment

165

Registered

2022-06-29

Start date

2015-09-29

Completion date

2025-12-30

Last updated

2022-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Hypertension

Brief summary

A little attention is paid to the AHT efficacy escaping problem, which can be explained by the AHT correction simplicity and rapid achievement of the target BP level. Nevertheless, modern statistic data on the effective AH treatment described above let us assume that AHT correction is either totally absent or is untimely in case of the escape phenomenon development. This could be one of the main reasons for the high prevalence of ineffective AH treatment. The aim of this study is to determine AHT efficacy escape phenomenon timeline and its predictors in hypertensive patients.

Interventions

DEVICEAmbulatory blood pressure measurement device

Assessment of the 24-h blood pressure profile

DEVICESphygmocor

Assessment of the arterial stiffness

DEVICEVaSera-VS

Assessment of the arterial stiffness

DEVICESomnocheck

Assessment of the sleep breath disturbances

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Arterial hypertension (AH) grade 1-3, stage I-II * High compliance during the follow-up period (≥ 85%) * Initially achieved target office BP levels while taking 2-3-component AHT

Exclusion criteria

* Secondary AH * Resistant AH, * AH III stage, * PAP- therapy, * type 2 diabetes mellitus, * pregnancy * history of low adherence to treatment

Design outcomes

Primary

Measure	Time frame	Description
Assessment of BP increasing higher the target level when taking the same therapy	1-6 months	Assessment of attenuation of efficacy of previously adequate antihypertensive therapy by using different BP measurement methods

Secondary

Measure	Time frame	Description
Disease course: assessment of major CVE and death occurrence	10 years	Assessment of the disease course depending on the characteristics of 3-6th months of observation

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026